248 results on '"Kwekkeboom, Jaap"'
Search Results
2. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells
3. Intestinal Bacteremia After Liver Transplantation Is a Risk Factor for Recurrence of Primary Sclerosing Cholangitis
4. Minimal Development of Liver Fibrosis in Adult Tolerant Liver Transplant Recipients Late After Immunosuppressive Drug Weaning and Transplantation
5. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
6. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance
7. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules
8. Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis
9. HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis
10. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma
11. LGR5 marks targetable tumor-initiating cells in mouse liver cancer
12. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa
13. Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infections
14. Donor‐specific anti‐HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation
15. Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients
16. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
17. 883 MCLA-145, an anti CD137×PD-L1 bispecific antibody, induces T cell activation and proliferation in ex vivo models of hepatocellular carcinoma
18. 1181 Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients
19. Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients
20. Kupffer Cells Interact With Hepatitis B Surface Antigen In Vivo and In Vitro, Leading to Proinflammatory Cytokine Production and Natural Killer Cell Function
21. Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid
22. Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection
23. Polarized release of hepatic microRNAs into bile and serum in response to cellular injury and impaired liver function
24. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
25. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
26. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
27. Activated CD4 + T Cells and Highly Differentiated Alloreactive CD4 + T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients
28. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
29. Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma
30. HLA matching and rabbit antithymocyte globulin as induction therapy to avoid multiple forms of rejection after a third liver transplantation
31. Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer
32. Targeting Gitr Enhances Human Tumour-infiltrating T Cell Functionality in Mismatch Repair Proficient Primary Colorectal Carcinoma and Liver Metastases
33. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
34. Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
35. 588 Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases
36. The biological process of lysine‐tRNA charging is therapeutically targetable in liver cancer
37. Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients.
38. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
39. Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance
40. Identification of a panel of safe immunogenic antigens for therapeutic vaccination strategies in hepatocellular carcinoma
41. TIGIT and PD1 dual checkpoint blockade restores functionality of tumor-infiltrating T cells in hepatocellular carcinoma
42. Expression of Cancer testis Antigens in Tumor-adjacent Normal Liver Predicts Post-resection Recurrence of Hepatocellular Carcinoma
43. Observed differences in the tumour microenvironment provide a potential explanation for the superior survival of patients with desmoplastic colorectal liver metastasis
44. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth
45. Characterization of Antigen-Presenting Cell Subsets in Human Liver-Draining Lymph Nodes
46. GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma
47. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma
48. Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma
49. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors
50. The biological process of lysine‐tRNA charging is therapeutically targetable in liver cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.